Abid Mohiuddin, MD
Hematology & Oncology · Monticello, ARNPI 1063526614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $994 and has fallen 72.7% since, to $271 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 155 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$632
- AstraZeneca$190
- Pfizer$142
- Sanofi$127
- Sobi, Inc$126
- Pharmacyclics LLC, An Abbvie Company$120
- plus $1K from 36 others
What the payments were for
- Food & beverage$2,66697%
- Education$923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $632 |
| AstraZeneca(2 entities) | 13 | $190 |
| Pfizer | 8 | $142 |
| Sanofi | 5 | $127 |
| Sobi, Inc | 6 | $126 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $120 |
| Coherus Oncology, Inc. | 8 | $109 |
| GSK | 2 | $101 |
| Beigene USA, Inc. | 5 | $86 |
| Amgen | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Johnson & Johnson | 4 | $66 |
| Boehringer Ingelheim | 3 | $61 |
| Seagen Inc. | 4 | $61 |
| Rigel Pharmaceuticals, Inc. | 3 | $57 |
| Karyopharm Therapeutics Inc. | 3 | $57 |
| Ipsen Biopharmaceuticals, Inc | 3 | $54 |
| Genentech, Inc. | 1 | $50 |
| Exelixis Inc. | 3 | $42 |
| Array Biopharma Inc | 2 | $41 |
| CTI Biopharma Corp. | 2 | $40 |
| EMD Serono, Inc. | 2 | $38 |
| Bristol Myers Squibb | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Gilead(2 entities) | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Bayer | 1 | $22 |
| Novocure Inc. | 1 | $20 |
| Caris MPI, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Epizyme, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$2,758 in reported general payments places this provider in the 40th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 12 | $22,631 |
| Imatinib Mesylate | 12 | $16,355 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $1,031 |
| Anastrozole | 31 | $408 |
| Pantoprazole Sodium | 13 | $406 |
| Potassium Chloride | 26 | $367 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $302 |
| Prednisone | 12 | $140 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Monticello
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
- Isam Abdel-KarimFort Smith$199K
- Appalanaidu SasapuLittle Rock$63K
- Stephan RosenfeldFayetteville$61K
- Stephen DiversHot Springs$55K
- Humdum DurraniFort Smith$54K
- Peter EmanuelLittle Rock$53K
- Patrick TravisFayetteville$37K
- Brad BaltzLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.